Cover Image
市場調查報告書

單株抗體治療藥的最新趨勢

Advances in Monoclonal Antibody Therapeutics

出版商 Technical Insights (Frost & Sullivan) 商品編碼 340911
出版日期 內容資訊 英文 94 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
單株抗體治療藥的最新趨勢 Advances in Monoclonal Antibody Therapeutics
出版日期: 2015年09月29日 內容資訊: 英文 94 Pages
簡介

單株抗體治療藥,尤其是用於腫瘤學和免疫學 (自體免疫疾病、發炎性疾病、移植的排斥反應等) 相關治療領域等廣泛領域的治療。醫藥品產業中、特定的細胞標導向的新分子劑的開發擔任重要角色。

本報告提供單株抗體治療藥的相關調查、單株抗體概要和治療藥市場趨勢,與產業概要最佳業務實踐、研究開發趨勢組合的策略性評估結果等彙整資料。

第1章 摘要整理

第2章 單株抗體

  • 技術概要
  • 產業概要
  • 精密醫療的技術藍圖

第3章 產業環境的策略性評估

  • 治療領域與臨床的適應
  • 分子劑和細胞標的
  • 開發階段
  • 市場潛力
  • 市場發展
  • 創業投資投資
  • 企業投資趨勢
  • 政府的捐助與支援
  • 全球的趨勢
  • 主要的促進因素與阻礙因素
  • 技術課題和商務課題

第4章 產業最佳業務實踐與策略性考察

  • 產業評估:聯盟與同盟
  • 聯盟的相關利益者評估
  • 聯盟與同盟模式
  • 聯盟與聯合
  • 專利分析
  • 專利趨勢
  • 各專利局趨勢

第5章 研究開發組合的策略性評估

  • 研究開發的成功和重要效能指標
  • 分析等級制度流程

第6章 重要聯絡處

第7章 附錄

目錄
Product Code: D65E-01-00-00-00

Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Research Scope
  • 2. Research Methodology
  • 3. Key Findings

2. MONOCLONAL ANTIBODIESA SNEAK PREVIEW

Monoclonal AntibodiesA Sneak Preview

  • 1. Technology Snapshot - Multiple Segmentation
  • 2. Industry Overview - Main Innovations
  • 3. Industry Overview - Main Innovators
  • 4. Technology Roadmap Toward Precision Medicine

3. STRATEGIC ASSESSMENT OF THE INDUSTRY ENVIRONMENT

Strategic Assessment of the Industry Environment

  • 1. Therapeutic Areas and Clinical Indications
  • 2. Molecular Agents and Cell Targets
  • 3. Developmental Stage Focus
  • 4. Market Potential
  • 5. Market Evolution
  • 6. Venture Capital Investment
  • 7. Company Stage Investment Focus
  • 8. Government Funding and Support
  • 9. Worldwide Landscape
  • 10. Key Drivers and Restraints
  • 11. Key Technical and Business Challenges

4. INDUSTRY BEST PRACTICES AND STRATEGIC INSIGHTS

Industry Best Practices and Strategic Insights

  • 1. Industry Assessment - Partnerships and Alliances
  • 2. Stakeholder Assessment for Partnerships
  • 3. Partnerships and Alliances Models
  • 4. Partnerships and Collaborations
  • 5. Partnerships and Collaborations (continued)
  • 6. Partnerships and Collaborations (continued)
  • 7. Patent Analysis
  • 8. Patent publishing trends
  • 9. Patent office-wise distribution

5. STRATEGIC EVALUATION OF R&D PORTFOLIO

Strategic Evaluation of R&D Portfolio

  • 1. R&D Success and Key Performance Indicators
  • 2. Analytical Hierarchy Process (AHP)
  • 3. Analytical Hierarchy Process (AHP)
  • 4. Analytical Hierarchy Process (AHP)
  • 5. Analytical Hierarchy Process (AHP)
  • 6. Analytical Hierarchy Process (AHP)
  • 7. Analytical Hierarchy Process (AHP)
  • 8. Analytical Hierarchy Process (AHP)
  • 9. Analytical Hierarchy Process (AHP)
  • 10. Analytical Hierarchy Process (AHP)

6. KEY CONTACTS

Key Contacts

  • 1. Contacts
  • 2. Contacts (continued)

7. APPENDIX

Appendix

  • 1. Strategic R&D Pipeline - The Road Ahead
  • 2. R&D Pipeline Assessment
  • 3. R&D Pipeline Assessment (continued)
  • 4. R&D Pipeline Assessment (continued)
  • 5. R&D Pipeline Assessment (continued)
  • 6. R&D Pipeline Assessment (continued)
  • 7. R&D Pipeline Assessment (continued)
  • 8. R&D Pipeline Assessment (continued)
  • 9. R&D Pipeline Assessment (continued)
  • 10. R&D Pipeline Assessment (continued)
  • 11. R&D Pipeline Assessment (continued)
  • 12. R&D Pipeline Assessment (continued)
  • 13. R&D Pipeline Assessment (continued)
  • 14. R&D Pipeline Assessment (continued)
  • 15. R&D Pipeline Assessment (continued)
  • 16. R&D Pipeline Assessment (continued)
  • 17. R&D Pipeline Assessment (continued)
  • 18. R&D Pipeline Assessment (continued)
  • 19. R&D Pipeline Assessment (continued)
  • 20. R&D Pipeline Assessment (continued)
  • 21. R&D Pipeline Assessment (continued)
  • 22. R&D Pipeline Assessment (continued)
  • 23. R&D Pipeline Assessment (continued)
  • 24. R&D Pipeline Assessment (continued)
  • 25. R&D Pipeline Assessment (continued)
  • 26. R&D Pipeline Assessment (continued)
  • 27. Product Line Assessment
  • 28. Product Line Assessment (continued)
  • 29. Product Line Assessment (continued)
  • 30. Product Line Assessment (continued)
  • 31. Product Line Assessment (continued)
  • 32. Product Line Assessment (continued)
  • 33. Product Line Assessment (continued)
  • 34. Product Line Assessment (continued)
  • 35. Product Line Assessment (continued)
  • 36. Product Line Assessment (continued)
  • 37. Abbreviations
  • 38. Legal Disclaimer
Back to Top